Longeveron

Longeveron Inc. (NASDAQ: LGVN), focusing on regenerative medicine, announced presentations at Biotech Showcase 2025 and Emerging Growth Conference, highlighting Lomecel-B's progress in treating HLHS and Alzheimer's. Roth MKM initiated coverage with a Buy rating, citing Lomecel-B's 100% transplant-free survival in HLHS. Longeveron also reported positive Q3 2024 financial results and advancements in clinical trials, including ELPIS II for HLHS and CLEAR MIND for Alzheimer's.

Celebrities endorse unregulated, expensive stem cell treatments lacking evidence and posing health risks. Despite potential, stem cells haven't fulfilled expectations, with a $2 billion industry offering unproven therapies. Legal loopholes allow clinics to sell treatments without proving safety or efficacy, risking patient health with minimal therapeutic effect.

Longeveron Inc., a regenerative biotechnology company, announced CEO Wa'el Hashad will present at Biotech Showcase on January 14, 2025. Their lead product, Lomecel-BTM, targets diseases like HLHS, Alzheimer's, and Aging-related Frailty, with FDA designations for HLHS and Alzheimer's programs.

Longeveron Inc., a biotech firm developing regenerative medicines, announced CEO Wa’el Hashad will present at Biotech Showcase 2025. Their lead product, Lomecel-B™, targets diseases like HLHS, Alzheimer’s, and Aging-related Frailty, with FDA designations for HLHS and Alzheimer’s programs.

Longeveron Inc. to present at the Emerging Growth Virtual Conference on Dec 5, 2024, at 12:00-12:30 p.m. ET. The webcast will be accessible on the company's website, with a replay available for 180 days. Questions can be submitted in advance or during the event.

Longeveron reports 80% enrollment in Phase 2b ELPIS II trial for HLHS, positive FDA Type C meeting confirming trial's pivotal status, and Phase 2a CLEAR MIND trial data in Alzheimer’s disease presented at AAIC. Total Revenue for Q1-Q3 2024 increased 177% to $1.8M, with reduced operating expenses and sufficient cash to fund operations through Q4 2025.

Longeveron Inc. appoints Devin Blass as CTO and SVP of CMC, effective December 2, 2024, to lead technological and manufacturing strategies. Blass brings over 15 years of experience in advanced therapies, most recently at New York Blood Center.

Longeveron Inc. appoints Devin Blass as CTO and SVP of CMC, effective December 2, 2024, to lead technological and manufacturing strategies. Blass, with over 15 years of experience in advanced therapies, previously served at NYBC and Talaris Therapeutics. He holds a BS in Biochemistry from Texas State University.

Lomecel-B™ inhibits MMP14, correlating with improved outcomes in mild Alzheimer’s disease, potentially protecting TIE2 receptor integrity and offering mechanistic insights for cellular therapy development.

Longeveron's ELPIS I study showed 100% 5-year survival with no heart transplants for HLHS patients treated with Lomecel-B™, compared to 83% survival in the SVR trial. ELPIS I met safety endpoints, and ELPIS II Phase 2b trial is ongoing to further evaluate Lomecel-B™.